Healthcare stocks advanced 1.6% at midday Monday.
The S&P 500 and the Nasdaq Composite index both closed 0.5% higher on Friday, reaching record highs on Wall Street.
BlinkLab (ASX:BB1) obtained institutional review board approval from US-based clinical research oversight provider WIRB-Copernicus Group for the main study phase of its US FDA 510(k) diagnostic trial evaluating the BlinkLab Dx 1 technology, a smartphone-based autism assessment tool.
On the flip side, the materials sector struggled, falling 1%, amid profit-taking from iron ore producers.
Mineral Resources (ASX:MIN) completed the sale of its Yilgarn iron ore assets and operations in Western Australia to Yilgarn Iron Investments, transferring ownership and all associated environmental and rehabilitation responsibilities. Yilgarn Iron will assume all environmental, closure, and rehabilitation liabilities, while the company retains the gold and lithium rights on the associated tenements.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。